Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy
Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 3212-3237
DOI: 10.1021/acs.jmedchem.4c02445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.01.2025. Verfasst von Shuqing Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Disease, Ministry of Education; Jiangxi Provincal Key Laboratory of …. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Histone Deacetylases, DNA Damage, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Bureau of Science and Technology of Ganzhou Municipality, National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
Histone deacetylase 3 (HDAC3) is a well-established target for cancer therapy. Herein, we developed LSQ-28 as a novel HDAC3 inhibitor, which exhibited high HDAC3 inhibitory activity (IC50 = 42 nM, SI > 161) and displayed potent antiproliferative activity against four cancer cells and further demonstrated excellent antimigratory, anti-invasive, and antiwound healing activities. Further studies revealed that LSQ-28 induced a dose-dependent increase in Ac-H3 expression and promoted the degradation of PD-L1. Additionally, LSQ-28 enhanced the DNA damage response induced by PARP inhibitor, as evidenced by regulated expression of PARP1 and γ-H2AX. Notably, LSQ-28 also possessed favorable pharmacokinetic properties with significant oral bioavailability (F = 95.34%). Importantly, the combination of LSQ-28 with the PD-L1 inhibitor NP-19 could enhance antitumor immune response (TGI = 80%). When combined with olaparib, LSQ-28 significantly enhanced the in vivo tumor-suppression activity (TGI = 91%). Collectively, LSQ-28 represents a promising HDAC3 inhibitor for further exploration in cancer therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Disease, Ministry of Education; Jiangxi Provincal Key Laboratory of Tissue Engineering; College of Pharmacy, Gannan Medical University, Ga…
ORCID-Profile: Xiaopeng Peng
Förderung
- Bureau of Science and Technology of Ganzhou Municipality
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- Gannan Medical University
- Jiangxi Provincial Key Laboratory of Tissue Engineering
Zitieren
APA
Li, S., Hu, Z., Pan, W., Wu, H., Peng, W., Wu, Y., Jiang, F., & Peng, X. (2025). Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy. Journal of Medicinal Chemistry, 68(3), 3212-3237. https://doi.org/10.1021/acs.jmedchem.4c02445
Vancouver
Li S, Hu Z, Pan W, Wu H, Peng W, Wu Y, et al. Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy. Journal of Medicinal Chemistry. 2025;68(3):3212-3237. doi:10.1021/acs.jmedchem.4c02445
BibTeX
@article{Li2025,
author = {Li, Shuqing and Hu, Zhihao and Pan, Wanyi and Wu, Haiyan and Peng, Weijie and Wu, Yi and Jiang, Feng and Peng, Xiaopeng},
title = {Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {3},
pages = {3212--3237},
doi = {10.1021/acs.jmedchem.4c02445}
}
EUVIMED